The IARC Perspective on Cervical Cancer Screening
Authors:
- 10 February 2022
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (6) , 607-608
Abstract
To the Editor: As discussed by Bouvard et al. (Nov. 11 issue),1 the International Agency for Research on Cancer (IARC), which evaluates screening and treatment strategies for cervical cancer, assigned an “A” rating to the quality of a cluster-randomized, controlled trial conducted in Mumbai, India.2 Reportedly, the Mumbai trial assessed the effectiveness of visual inspection with acetic acid (VIA) for cervical cancer screening as compared with no screening.1,2 However, documents obtained through the U.S. Freedom of Information Act established that the Mumbai trial assessed the effectiveness of unaided visual inspection, a cervical cancer screening test that cannot detect precancerous cervical lesions . . .Keywords
This publication has 2 references indexed in Scilit:
- The IARC Perspective on Cervical Cancer ScreeningNew England Journal of Medicine, 2021
- Effect of VIA Screening by Primary Health Workers: Randomized Controlled Study in Mumbai, IndiaJNCI: Journal of the National Cancer Institute, 2014